Atherosclerosis

Atherosclerosis is when arteries get hardened and narrowed. Learn what causes it, how it harms your health, and what you can do to prevent it.  

More than half say they will change their practice after findings that women who started HRT less than 6 years after menopause had slower progression of atherosclerosis; plenty of uncertainty remains.  

European Atherosclerosis Society (EAS) 2016 Annual Congress: Read clinically focused news coverage of key developments from EAS 2016.  

Premature atherosclerosis has been observed among HIV-infected individuals with high cardiovascular risk. Should HIV patients who were categorized as low cardiovascular risk also be worried?  

Drs Leslie Cooper and Amy Pollak debunk misconceptions on the diagnosis and treatment of PAD.  

: Estradiol taken within 6 years vs 10 years or more after menopause was associated with a lower risk for progression of subclinical atherosclerosis, based on results from an intervention trial.  

"The cardiovascular hazards of carbonated beverage consumption are evident even in the subclinical stages of atherosclerosis," report the investigators.  

Atheromatous vascular disease  

This review explores the role of invasive and non-invasive cardiovascular imaging in risk assessment in atherosclerosis. What insights can imaging provide about plaque pathophysiology and evolution?  

The goal of this activity is to increase clinicians' understanding of the impact of eicosapentaenoic acid (EPA) on mixed dyslipidemia and atherosclerosis and thereby enabling more effective treatment management for these high-risk patients.  

Treatment effects from randomised trials are typically expressed as numbers needed to treat to prevent one adverse disease event during a fixed time interval (eg, five or 10 years). In the actual patient, however, many diseases are chronically progressive, despite treatment. Examples are diabetic nephropathy, some types of malignancies, osteoporosis, and atherosclerosis. In these examples, the aim of treatment is not to prevent but to delay the occurrence of symptomatic disease. Thus the actual effect of treatment is gain in disease-free life expectancy  

Treatment effects from randomised trials are typically expressed as numbers needed to treat to prevent one adverse disease event during a fixed time interval (eg, five or 10 years). In the actual patient, however, many diseases are chronically progressive, despite treatment. Examples are diabetic nephropathy, some types of malignancies, osteoporosis, and atherosclerosis. In these examples, the aim of treatment is not to prevent but to delay the occurrence of symptomatic disease. Thus the actual effect of treatment is gain in disease-free life expectancy  

Women taking estradiol within 6 years of menopause had a lower risk for progression of subclinical atherosclerosis compared with those taking it 10 or more years after menopause.  

Treatment effects from randomised trials are typically expressed as numbers needed to treat to prevent one adverse disease event during a fixed time interval (eg, five or 10 years). In the actual patient, however, many diseases are chronically progressive, despite treatment. Examples are diabetic nephropathy, some types of malignancies, osteoporosis, and atherosclerosis. In these examples, the aim of treatment is not to prevent but to delay the occurrence of symptomatic disease. Thus the actual effect of treatment is gain in disease-free life expectancy  

Treatment effects from randomised trials are typically expressed as numbers needed to treat to prevent one adverse disease event during a fixed time interval (eg, five or 10 years). In the actual patient, however, many diseases are chronically progressive, despite treatment. Examples are diabetic nephropathy, some types of malignancies, osteoporosis, and atherosclerosis. In these examples, the aim of treatment is not to prevent but to delay the occurrence of symptomatic disease. Thus the actual effect of treatment is gain in disease-free life expectancy  

What is the relationship between NAFLD, metabolic syndrome, and subclinical atherosclerosis markers?  

Ambulatory heart rate, but not HR by office readings, was "associated with known risk factors for atherosclerosis prior to the development of diabetes or sustained hypertension," researchers found.  

In a substudy of the Veterans Affairs Diabetes Trial, serious hypoglycemia was linked to atherosclerosis progression in the standard but not the intensive-treatment group.  

Two small RCTs (Ahimastos et al. 2006, n=40 and Shahin et al. 2013a, n=33) found that, compared with placebo, over 24 weeks, ramipril 10 mg daily improved maximum and pain‑free walking times and distances in people with stable intermittent claudication, a symptom of peripheral arterial disease. However, while these differences were statistically significant, the clinical importance of the results is unclear. No adverse effects were reported in 1 study. In the other study, the adverse effect most often reported with ramipril was cough, which led to discontinuation in some cases.  

NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease.